Your browser doesn't support javascript.
loading
Activation of the Amino Acid Response Pathway Blunts the Effects of Cardiac Stress.
Qin, Pu; Arabacilar, Pelin; Bernard, Roberta E; Bao, Weike; Olzinski, Alan R; Guo, Yuanjun; Lal, Hind; Eisennagel, Stephen H; Platchek, Michael C; Xie, Wensheng; Del Rosario, Julius; Nayal, Mohamad; Lu, Quinn; Roethke, Theresa; Schnackenberg, Christine G; Wright, Fe; Quaile, Michael P; Halsey, Wendy S; Hughes, Ashley M; Sathe, Ganesh M; Livi, George P; Kirkpatrick, Robert B; Qu, Xiaoyan A; Rajpal, Deepak K; Faelth Savitski, Maria; Bantscheff, Marcus; Joberty, Gerard; Bergamini, Giovanna; Force, Thomas L; Gatto, Gregory J; Hu, Erding; Willette, Robert N.
Afiliación
  • Qin P; Heart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapy Area GlaxoSmithKline, King of Prussia, PA pu.2.qin@gsk.com.
  • Arabacilar P; Heart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapy Area GlaxoSmithKline, King of Prussia, PA.
  • Bernard RE; Heart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapy Area GlaxoSmithKline, King of Prussia, PA.
  • Bao W; Heart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapy Area GlaxoSmithKline, King of Prussia, PA.
  • Olzinski AR; Heart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapy Area GlaxoSmithKline, King of Prussia, PA.
  • Guo Y; Basic & Translational Research, School of Medicine, Vanderbilt University, Nashville, TN.
  • Lal H; Basic & Translational Research, School of Medicine, Vanderbilt University, Nashville, TN.
  • Eisennagel SH; Heart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapy Area GlaxoSmithKline, King of Prussia, PA.
  • Platchek MC; Target and Pathway Validation, Target Sciences, GlaxoSmithKline, King of Prussia, PA.
  • Xie W; Target and Pathway Validation, Target Sciences, GlaxoSmithKline, King of Prussia, PA.
  • Del Rosario J; Heart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapy Area GlaxoSmithKline, King of Prussia, PA.
  • Nayal M; Heart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapy Area GlaxoSmithKline, King of Prussia, PA.
  • Lu Q; Target and Pathway Validation, Target Sciences, GlaxoSmithKline, King of Prussia, PA.
  • Roethke T; Heart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapy Area GlaxoSmithKline, King of Prussia, PA.
  • Schnackenberg CG; Heart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapy Area GlaxoSmithKline, King of Prussia, PA.
  • Wright F; Preclinical and Translational Imaging, Platform Technology and Science, GlaxoSmithKline, King of Prussia, PA.
  • Quaile MP; Preclinical and Translational Imaging, Platform Technology and Science, GlaxoSmithKline, King of Prussia, PA.
  • Halsey WS; Target and Pathway Validation, Target Sciences, GlaxoSmithKline, King of Prussia, PA.
  • Hughes AM; Target and Pathway Validation, Target Sciences, GlaxoSmithKline, King of Prussia, PA.
  • Sathe GM; Target and Pathway Validation, Target Sciences, GlaxoSmithKline, King of Prussia, PA.
  • Livi GP; Target and Pathway Validation, Target Sciences, GlaxoSmithKline, King of Prussia, PA.
  • Kirkpatrick RB; Pipeline Future's Group, GlaxoSmithKline, King of Prussia, PA.
  • Qu XA; Computational Biology, Projects Clinical Platforms and Sciences, GlaxoSmithKline, King of Prussia, PA.
  • Rajpal DK; Computational Biology, Projects Clinical Platforms and Sciences, GlaxoSmithKline, King of Prussia, PA.
  • Faelth Savitski M; Cellzome GmbH, A GSK Company, GlaxoSmithKline, King of Prussia, PA.
  • Bantscheff M; Cellzome GmbH, A GSK Company, GlaxoSmithKline, King of Prussia, PA.
  • Joberty G; Cellzome GmbH, A GSK Company, GlaxoSmithKline, King of Prussia, PA.
  • Bergamini G; Cellzome GmbH, A GSK Company, GlaxoSmithKline, King of Prussia, PA.
  • Force TL; Basic & Translational Research, School of Medicine, Vanderbilt University, Nashville, TN.
  • Gatto GJ; Heart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapy Area GlaxoSmithKline, King of Prussia, PA.
  • Hu E; Heart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapy Area GlaxoSmithKline, King of Prussia, PA.
  • Willette RN; Heart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapy Area GlaxoSmithKline, King of Prussia, PA.
J Am Heart Assoc ; 6(5)2017 May 09.
Article en En | MEDLINE | ID: mdl-28487390
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Piperidinas / Estrés Fisiológico / Inhibidores de la Síntesis de la Proteína / Miocitos Cardíacos / Inhibidores Enzimáticos / Quinazolinonas / Fibroblastos / Aminoácidos / Insuficiencia Cardíaca Tipo de estudio: Prognostic_studies Límite: Animals / Humans / Male Idioma: En Revista: J Am Heart Assoc Año: 2017 Tipo del documento: Article País de afiliación: Panamá
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Piperidinas / Estrés Fisiológico / Inhibidores de la Síntesis de la Proteína / Miocitos Cardíacos / Inhibidores Enzimáticos / Quinazolinonas / Fibroblastos / Aminoácidos / Insuficiencia Cardíaca Tipo de estudio: Prognostic_studies Límite: Animals / Humans / Male Idioma: En Revista: J Am Heart Assoc Año: 2017 Tipo del documento: Article País de afiliación: Panamá